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Abstract
Background: Deregulated metabolism is a hallmark of cancer and recent evidence underlines that targeting tumor
energetics may improve therapy response and patient outcome. Despite the general attitude of cancer cells to
exploit the glycolytic pathway even in the presence of oxygen (aerobic glycolysis or “Warburg effect”), tumor
metabolism is extremely plastic, and such ability to switch from glycolysis to oxidative phosphorylation (OxPhos)
allows cancer cells to survive under hostile microenvironments. Recently, OxPhos has been related with malignant
progression, chemo-resistance and metastasis. OxPhos is induced under extracellular acidosis, a well-known
characteristic of most solid tumors, included melanoma.
Methods: To evaluate whether SOX2 modulation is correlated with metabolic changes under standard or acidic
conditions, SOX2 was silenced and overexpressed in several melanoma cell lines. To demonstrate that SOX2 directly
represses HIF1A expression we used chromatin immunoprecipitation (ChIP) and luciferase assay.
Results: In A375-M6 melanoma cells, extracellular acidosis increases SOX2 expression, that sustains the oxidative
cancer metabolism exploited under acidic conditions. By studying non-acidic SSM2c and 501-Mel melanoma cells
(high- and very low-SOX2 expressing cells, respectively), we confirmed the metabolic role of SOX2, attributing
SOX2-driven OxPhos reprogramming to HIF1α pathway disruption.
Conclusions: SOX2 contributes to the acquisition of an aggressive oxidative tumor phenotype, endowed with
enhanced drug resistance and metastatic ability.
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Background
In the last decades, tumor metabolism has drawn in-
creasing attention in the scientific world and deregu-
lating cellular energetics has recently become a
hallmark of cancer [1]. Instead of using an oxidative
metabolism like most of normal cells, cancer cells con-
vert glucose into lactate even in the presence of high
oxygen tension, exploiting the so-called aerobic gly-
colysis or “Warburg effect”. Despite the energetic gain
in terms of ATP production is lower than during the
oxidative phosphorylation (OxPhos), the Warburg me-
tabolism is about 100-fold faster than OxPhos and en-
sures biomass formation and DNA duplication, that is
crucial for cancer cell proliferation [2]. Indeed, fermen-
tation to lactic acid and the glycolytic breakdown of
glucose generate a number of substrates which turn
into “anabolic” precursors for the synthesis of different
compounds, such as glucose-6-phosphate for glycogen
and ribose 5-phosphate, dihydroxyacetone phosphate
for triacylglyceride and phospholipids, and pyruvate
for alanine and malate. Metabolite accumulation up-
stream pyruvate production is further increased by the
up-regulation of the low activity M2 isoform of pyru-
vate kinase (PKM2), that slows down the last step of
glycolysis. In this respect, intermediate components of
the glycolytic pathway appear to be more significant
than its final product pyruvate. Given the limited
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pyruvate supply, to replenish the tricarboxylic acid
cycle (TCA) cancer cells increase glutamine consump-
tion, a key nutrient that provides carbon for
acetyl-CoA, citrate production and lipogenesis, nitro-
gen for purine, pyrimidine and DNA synthesis, and re-
ducing power in the form of NADPH to support cell
proliferation [3]. The particular attitude of proliferat-
ing cancer cells to use aerobic glycolysis favors a
microenvironment enriched in lactate and protons,
with a subsequent pH reduction. Moreover, the large
amount of lactate released by tumor cells can be taken
up by normal stromal cells to regenerate pyruvate,
which in turn can be extruded to refuel cancer cells
[4]. The reduction in oxygen tension that characterizes
proliferating tumor tissues, stimulates the hypoxia-in-
ducible factor α (HIF1α), which drives the anaerobic
glycolysis. This leads to lactate dehydrogenase A
(LDH-A)-dependent lactic acid production, and the
upregulation of monocarboxylated transporter (MCT)-
4 and of sodium-proton exporters to avoid intracellular
acidosis. As a direct consequence, both aerobic and an-
aerobic glycolysis adopted by cancer cells contribute to
the acidification of tumor microenvironment. Dysregu-
lated pH is emerging as a hallmark of cancer, since
cancer cells show a ‘reversed’ pH gradient with a con-
stitutively increased intracellular pH (pHi) that is
higher than the extracellular pH (pHe). Indeed, while
normal differentiated adult cells show pHi of ∼7.2 and
pHe of ∼7.4, cancer cells have a higher pHi (> 7.4) and
a lower pHe (6.7–7.1). This ‘reversed’ pH gradient cre-
ates a perfect storm for metastatic progression [5] by
promoting malignant phenotype endowed with apop-
tosis resistance, radio- and chemotherapy resistance,
immune surveillance escape programs, increased mi-
gration and ability of secondary organs colonization
[6]. As an additional aspect, we have recently reported
that acidic cancer cells undergo a metabolic change
characterized by the acquisition of a more OxPhos
phenotype through the inhibition of HIF1α expression,
associated with a reduced proliferation compared to
standard pH condition [7].
Tumor cells are extremely plastic even in terms of
cellular energetics and may shift their metabolic phe-
notypes to adapt to microenvironmental changes, giv-
ing a selective advantage to cancer cells under
unfavourable environments [8]. Most of solid tumors,
including melanoma, undergo such plastic changes in
metabolism. Cutaneous melanoma, despite represent-
ing less than 5% of all skin cancers, is responsible for
the majority of skin cancer-related deaths [9]. The inci-
dence of malignant melanoma in most developed
countries has risen faster than any other cancer type
since the mid-1950s. It is estimated that the annual in-
crease in the incidence rate of melanoma has been
approximately 3–7% per year worldwide for Cauca-
sians. Detection and surgical treatment of early-stage
disease seems to prevent progression in most cases.
However, patients with deep primary tumors or tumors
that metastasize to regional lymph nodes frequently
develop distant metastases. Median survival after the
onset of distant metastases is only 6–9 months, and
the 5-year survival rate is less than 5% [10].
Recent studies have pointed out the crucial role of
the transcription factor SOX2 (sex-determining region
Y (SRY)-Box2) in melanoma and cancer in general.
SOX2 has been correlated with growth, tumorigenicity,
drug resistance, and metastasis in at least 25 different
tumors, including cancers of the ovary, lung, skin,
brain, breast, prostate, and pancreas [11]. In the major-
ity of these cancers, SOX2 has been found to have in-
creased expression or gene amplification in tumor
tissues. Moreover, SOX2 has been associated with
stemness and tumor initiating cells (TICs), proposed
to explain origin and heterogeneity of many tumors
[12], including cervical, lung, ovarian, head and neck
squamous cell carcinoma, medulloblastoma, skin
squamous-cell carcinoma, and melanoma [11]. Indeed,
SOX2 has been reported to regulate self-renewal and
tumorigenicity of human melanoma-initiating cells
[13, 14]. Previous reports indicate that SOX2 is
expressed in 50% of melanomas and a minority of nevi
[15–17], and is associated with dermal invasion and
primary tumor thickness [18]. However, the role of
SOX2 in melanoma growth and progression is more
controversial. While an early paper reported that
SOX2 silencing reduces in vivo growth of A2058 mel-
anoma cells [15], recent studies suggest that SOX2 is
dispensable for melanomagenesis and metastasis
formation [19, 20].
Here we show for the first time that SOX2 is highly
expressed in melanoma cells exposed to extracellular
acidosis, where it modulates cell metabolism in order
to favor an oxidative phenotype, possibly interfering
with HIF1α expression. This additional attitude of
SOX2 might add new information on its crucial im-
portance in malignant progression.
Methods
Cell cultures
A375-M6 [21], commercial 501-Mel, SK-Mel-2, SK-
Mel-5, SK-Mel-28 and patient-derived SSM2c [13]
melanoma cell lines were maintained in DMEM 4.5 g/l
glucose, 2 mM L-glutamine, and 10% FBS (Euroclone,
Milan Italy). 24-h medium acidification was obtained
by adding HCl 1 N in complete culture medium to
reach pH 6.7 ± 0.1. pH value was monitored by using
Orion pH meter 520A-1. pH was monitored for the
first hour after medium acidification to check the
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maintenance of a pH value at 6.7, and then at the end
point of each experiment. Cells were treated with 50
mM 2-deoxyglucose (Calbiochem, San Diego, CA,
USA) or 10 mM Metformin (Sigma-Aldrich, Milan,
Italy) for 24 h.
SOX2 silencing and overexpression
SOX2-silenced A375-M6 cells were obtained by siRNA
transfection with Sox-2 siRNA (sc-38408, Santa Cruz Bio-
technology, Dallas, Texas, USA) or control siRNA-A
(sc-37007, Santa Cruz Biotechnology), according to manu-
facturer’s instructions. SOX2 silencing in SSM2c cells was
obtained by lentiviral transduction. Lentiviruses were pro-
duced in HEK-293 T cells. Lentiviral vectors used were
pLKO.1-puro (LV-c) (Open Biosystems, Lafayette, CO,
USA) and pLKO.1-puro-shSOX2–1 (LV-shSOX2–1)
targeting the 3′ untranslated region of SOX2 (targeting se-
quence 5’-CTGCCGAGAATCCATGTATAT-3′) as previ-
ously reported [13]. SOX2 overexpression in 501-Mel cells
was obtained by retroviral transduction. Retroviruses were
produced in HEK-293 T cells. Retroviral vectors used were
generated by co-transfection of 1 μg pBABE (Addgene,
Cambridge, MA, USA, #1764) or pBABE-SOX2 (cloned
into the BamHI/SalI restriction sites of pBABE vector
using the following primers: SOX2-F 5’-ATGTACAAC
ATGATGGAGACGG-3′ and SOX2-R 5’-TCACATGTG
TGAGAGGGGC-3′), 0.9 μg pUMVC packaging plasmid
(Addgene, #8449) and 0.1 μg pCMV-VSV-G envelope
(Addgene, #8454).
Western blot analysis
Cells were lysed in RIPA buffer (Merck Millipore) contain-
ing PMSF (Sigma-Aldrich), sodium orthovanadate (Sig-
ma-Aldrich), and protease inhibitor cocktail (Calbiochem),
sonicated and centrifuged 15min at 14,000 rpm at 4 °C.
Equal amounts of protein were separated on Bolt® Bis-Tris
Plus gels, 4–12% precast polyacrylamide gels (Life Tech-
nologies, Milan, Italy). Fractionated proteins were trans-
ferred to a PVDF membrane using the iBlot 2 System (Life
Technologies). Following 1-h blocking with Odyssey block-
ing buffer (Dasit Science, Milan, Italy), membrane was
probed overnight at 4 °C with the following primary anti-
bodies: anti-SOX2 mouse monoclonal antibody (R&D
System, Minneapolis, MN, USA), anti-HIF-1α rabbit poly-
clonal antibody (Novusbio, Milan, Italy), anti- GLUT-1,
GLUT-3, MCT-1, MCT-4 and PGC1α rabbit polyclonal
antibodies (Santa Cruz Biotechnology). After that, mem-
brane was incubated 1 h at room temperature with goat
anti-mouse IgG Alexa Fluor 680 antibody (Invitrogen) or
goat anti-rabbit IgG Alexa Flour 750 antibody (Invitrogen-
Life Technologies, Milan, Italy). Membrane was visualized
by the Odyssey Infrared Imaging System (LI-COR®
Bioscience, Lincoln, Nebraska USA). Anti-HSP90 (Santa
Cruz Biotechnology), β-actin (Sigma-Aldrich) and HDAC2
(Santa Cruz Biotechnology) antibodies were used to assess
equal amount of protein loaded in each lane.
Flow cytometry
Cells were harvested by using Accutase (Euroclone),
collected in flow cytometer tubes (2 × 105 cells/tube),
permeabilized for 15 min with 0.25% Tryton X-100
PBS, and incubated 1 h at 4 °C with anti-SOX2 anti-
body (Santa Cruz Biotechnology). Cells were washed in
PBS and incubated 1 h in the dark at 4 °C with
anti-goat antibody conjugated with FITC (Merk Milli-
pore, Milan, Italy). Samples were washed in PBS and
the analyzed at BD FACSCanto (BD Biosciences,
Milan, Italy). The flow cytometer was calibrated using
cells incubated with secondary antibody only. For each
sample, 1 × 104 events were analysed.
Lactate production
Lactate production by cancer cells was evaluated in 24-h
conditioned medium by using D-Lactate Colorimetric
Assay Kit (Biovision, CA, USA) according to manufac-
turer’s instructions. The analysis was performed at the
microplate reader (Bio-Rad, Milan, Italy) and data normal-
ized for the cell number of each sample, to get a final re-
sult of lactate production (nM) by 1 × 105 cells.
Glucose uptake detection
Glucose uptake by melanoma cells was evaluated by using
Glucose Uptake Cell-Based Assay Kit (Cayman Chemical,
Michigan, USA) according to manufacturer’s instructions.
Briefly, melanoma cells were glucose-starved for 1 h by
using RPMI medium without glucose (Euroclone), then
incubated for 15min in the dark with 2-NBDG, a
FITC-labeled deoxyglucose analog, harvested and ana-
lyzed at BD FACSCanto (BD Biosciences). The flow cyt-
ometer was calibrated using untreated cells. For each
sample, 1 × 104 events were analyzed.
Quantitative real time PCR (qPCR)
Total RNA was prepared using Tri Reagent (Sigma-Aldrich),
agarose gel checked for integrity, and reverse transcribed
with iScript cDNA Synthesis Kit (Bio-Rad) according to the
manufacturer’s instructions. Selected genes were evaluated
by a real-time RT-PCR with 7500 Fast Real-Time PCR Sys-
tem (Applied Biosystems, Monza, Italy). Fold change was de-
termined by the comparative Ct method using β-actin,
TATA sequence binding protein (TBP), glyceraldehyde
3-phosphate dehydrogenase (GAPDH) and β2-microglobulin
as housekeeping genes. Amplification was performed with
the PCR setting: 40 cycles of 95 °C for 15 s and of 60 °C for
60 s using PowerUp SYBR Green Master Mix (Thermo
Fisher Scientific). Primer sequences (IDT, Tema Ricerca, Bol-
ogna, Italy) are listed in Table 1.
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Annexin V/PI flow cytometer analysis
Cell death was determined by flow cytometer analysis
using Annexin V FITC-conjugated (Immunotools GmbH,
Friesoythe, Germany) and PI (Sigma-Aldrich) according
to the manufacturer’s protocol. Briefly, cells were har-
vested with Accutase (Eurolone), collected in flow cyt-
ometer tubes (1 × 105 cells/tube), washed in PBS, and
incubated 15min at 4 °C in the dark with 100 μl Annexin
binding buffer (100mM HEPES, 140mM NaCl, 25mM
CaCl2, pH 7.4), 1 μl of 100 μg/ml PI working solution, and
5 μl Annexin V FITC-conjugated. Each sample was added
with Annexin binding buffer to reach 500 μl volume/tube.
Samples were analyzed at BD FACSCanto (BD Biosci-
ences). Cellular distribution depending on Annexin V
and/or PI positivity allowed the measure of the percentage
of viable cells (Annexin V and PI negative cells), early
apoptosis (Annexin V-positive and PI negative cells), late
apoptosis (Annexin V and PI-positive cells), and necrosis
(Annexin V-negative and PI-positive cells).
Chromatin immunoprecipitation
Melanoma cells were fixed with 1% formaldehyde for
10 min and lysed in cell Lysis Buffer (5 mM PIPES pH
8, 85 mM KCl, 0.5% NP-40) added with protease inhib-
itors. Nuclei were collected by centrifugation at 4500
rpm for 10 min and lysed in nuclear lysis buffer (1%
SDS, 10 mM EDTA, 50 mM Tris-HCl pH 8) added with
protease inhibitors. Chromatin was sonicated to an
average size of 200–600 bp, diluted with ChIP Dilution
Buffer (10 mM Tris-HCl pH 8, 1% Triton X-100, 2 mM
EDTA, 140 mM NaCl) and incubated overnight with
20 μl of protein G magnetic dynabeads pre-conjugated
with mouse anti-SOX2 (MAB2018; R&D System) or
normal mouse IgG (sc-2025; Santa Cruz Biotechnology)
antibodies. DNA was purified and qPCR was carried out
at 60 °C using FastStart SYBR Green Master (Roche Diag-
nostic, Monza, Italy) in a Rotorgene-Q (Qiagen, Milan,
Italy). Primer sequences are listed in Table 1.
Luciferase reporter assays
Luciferase reporters were used in combination with
Renilla luciferase pRL-TK reporter vector (Promega,
Madison, WI) to normalize luciferase activities. pCS2 +
MT vector (Promega) was used to equal DNA amounts;
pCS2 + SOX2 was cloned into pCS2 +MT using the fol-
lowing primers: Fwd 5’-ATGTACAACATGATGGAGA
CGG-3′, Rev. 5’-CACATGTGTGAGAGGGGC-3′ after
digestion with XhoI/SnaBI restriction enzymes; pGL4.20-
HIF1αprom was purchase from Addgene (Plasmid
#40173). Luminescence was measured using the Dual-Glo
Luciferase Assay System (Promega) and the GloMax® 20/
20 Luminometer (Promega).
Statistical analysis
The experiments were performed at least three times
for a reliable application of statistics. Statistical ana-
lysis was performed with GraphPad Prism software.
Values are presented as mean ± SD. ANOVA or Stu-
dent’s T test were used to evaluate the statistical
significance.
Results
Extracellular acidosis promotes SOX2 expression in
melanoma cells contributing to OxPhos metabolism
We have previously investigated the role of acidic
tumor microenvironment in the acquisition of an ag-
gressive [22] and chemo-resistant [23] phenotype in
melanoma cells and found a closely related metabolic
reprogramming that switches acidic cells to a more
oxidative metabolism [7]. In this context, we hypothe-
sized that the expression of the transcription factor
SOX2 might be modulated by pH variations of tumor
extracellular microenvironment and have a role in this
metabolic adaptation. Flow cytometry and western blot
analyses (Fig. 1a and b) showed increased SOX2 ex-
pression in A375-M6 melanoma cells exposed to acidic
medium (pH 6.7) compared to control (pH 7.4). We
also observed that SOX2 expression was strictly regu-
lated by pH variations: while pH 7.0 was not sufficient
to increase SOX2 expression, we obtained a maximal
Table 1 List of forward and reverse primers used for qPCR analysis
Gene Forward Reverse
GLUT1 CGGGCCAAGAGTGTGCTAA TGACGATACCGGAGCCAATG
GLUT3 CGAACTTCCTAGTCGGATTG AGGAGGCACGACTTAGACAT
HK2 CAAAGTGACAGTGGGTGTGG GCCAGGTCCTTCACTGTCTC
LDHA AGGGAATGTACGGCATTGAG CCTCATCGTCCTTCAGCTTC
PDK1 CCAAGACCTCGTGTTGAGACC AATACACGTCTCAGGTCTC
CTTGG
PDP2 TAGGCCAACCTTTGTTTCACCA AGACCCTCACAACAAAAGCCT
MCT-1 GTGGCTCAGCTCCGTATTGT GAGCCGACCTAAAAGTGGTG
MCT-4 CAGTTCGAGGTGCTCATGG ATGTAGAGGTGGGTCGCATC
PGC1α GGGAAAGTGAGCGATTAGTTGAG CATGTAGAATTGGCAGGTGGAA
CytC TTGCACTTACACCGGTACTTAAGC ACGTCCCCACTCTCTAAGTCCAA
COX4I GGCCCGGCATTTTACGA TCACCGTGGAGCGGAAA
COX5b TGCGCTCCATGGCATCA CCCAGTCGCCTGCTCTTC
ATP5A1 TGCAAGGACTTCCATGCCTC CGCCCAGGTTCTTCAAGATCAA
SOX2 GAGCTTTGCAGGAAGTTTGC GCAAGAAGCCTCTCCTTGAA
HIF1a
promoter
TGCAAAGTTGCCAAAGGCCA CAGGGGAACTCACCTTGTCTAC
HIF1a GGCGCGAACGACAAGAAAAA TCCAAATCACCAGCATCCAGA
TBP CAACAGCCTGCCACCTTAC CTGAATAGGCTGTGGGGTC
ACTIN TCGAGCCATAAAAGGCAACT CTTCCTCAATCTCGCTCTCG
GAPDH GACGCTGGGGCTGGCATTG GCTGGTGGTCCAGGGGTC
Β2-
microglobulin
GCCGTGTGAACCATGTGACT GCTTACATGTCTCGATCCCACTT
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level at pH 6.7, but further medium acidification up to
pH 6.4 restored SOX2 expression at control level (Fig.
1c). As previously reported [7], extracellular acidosis
induces a metabolic shift towards OxPhos with a sim-
ultaneous slowdown of the glycolytic pathway, as
confirmed by the reduced lactate production (Fig. 1d)
and glucose uptake (Fig. 1e) by acidosis-exposed mel-
anoma cells compared to control. To understand
whether SOX2 up-regulation in acidic melanoma cells
might be implicated in the reconversion to OxPhos
a b
c d
e f g
h
j k
i
Fig. 1 SOX2 is up-regulated by extracellular acidosis and its inhibition increases the glycolytic metabolism in A375-M6 melanoma cells. a, b)
Representative flow cytometry plot (left) and relative quantification chart (right) (a) and Western blot (b) of SOX2 in A375-M6 cells exposed for 24
h to standard pH 7.4 and acidic pH 6.7. p < 0.05, T-test. N = 3. HDAC2 was used as loading control of nuclear protein fraction. Quantification of
SOX2 protein expression in shown in italic. c) Representative flow cytometry plot (left) and relative quantification chart (right) of SOX2 level
variation along with pH values. p < 0.01, T-test, N = 3. d) Quantification of lactate production by A375-M6 cells exposed for 24 h to standard (pH
7.4) or acidic (pH 6.7) conditions. p < 0.01, T-test, N = 3. e) Representative flow cytometry plot (left) and quantification of glucose uptake (right) in
A375-M6 cells exposed for 24 h to standard (pH 7.4) or acidic (pH 6.7) conditions. p < 0.05, T-test, N = 3. f, g) Quantitative Real Time PCR (qPCR) (f)
and Western blot (g) of SOX2 in A375-M6 silenced for SOX2 (siSOX2) compared to control (siCTRL). Quantification of SOX2 protein is shown in
italic. β-actin used as loading control. p < 0.01, T-test. N = 3. h) Quantification chart of lactate production by A375-M6 siSOX2 compared to siCTRL
in standard condition (pH 7.4) p < 0.01, T-test, N = 3. i) qPCR of a panel of glycolysis- and OxPhos-related genes of A375-M6 in standard condition
(pH 7.4) silenced for SOX2 (siSOX2) compared to control (siCTRL). *p < 0.05, **p < 0.01; ***p < 0.001, T-test, N = 3. j) Quantification chart of lactate
production by acidosis-exposed (pH 6.7) siSOX2 A375-M6 compared siCTRL. p < 0.01, T-test, N = 3. k) qPCR analysis of a panel of glycolysis- and
OxPhos-related genes of acidosis-exposed (pH 6.7) A375-M6 siSOX2 compared siCTRL. *p < 0.05, **p < 0.01, ***p < 0.001, T-test. N = 3
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metabolism, SOX2 was silenced (Fig. 1f and g). Lower-
ing SOX2 level in melanoma cells, besides causing a
decrease in cell proliferation (Additional file 1: Figure
S1a) in accordance with the literature [13], correlated
with a more glycolytic metabolism, as confirmed by
augmented lactate production (Fig. 1h) and the incre-
ment of glycolytic gene expression together with a re-
duction of oxidative ones (Fig. 1i and Additional file 1:
Figure S2). This change in metabolism elicited by
SOX2 silencing was also evident in melanoma cells ex-
posed to extracellular acidosis (pH 6.7) (Fig. 1j and k),
confirming the contribution of SOX2 to the OxPhos
metabolic adaptation. Indeed, SOX2 silencing in mel-
anoma cells, under both standard and acidic condi-
tions, favored an enhanced expression of glucose
transporters GLUT-1 and GLUT-3. Further, hexokinase
isoform 2 (HK2), which catalyzes the rate-limiting first
step of glycolysis, was stimulated upon SOX2 silencing
in either standard or acidic cells, although in acidic
cells does not reach a significantly level (Fig. 1i and
Additional file 1: Figure S2). To evaluate the activity of
pyruvate dehydrogenase (PDH) enzyme, which drives
the pyruvate enter into TCA cycle linking glycolysis to
OxPhos, we tested the expression of two enzymes that
regulate PDH: the activating pyruvate dehydrogenase
phosphatase 2 (PDP2) and the inhibiting pyruvate de-
hydrogenase kinase 1 (PDK1). In SOX2-silenced con-
trol and acidic melanoma cells, we observed reduction
of PDP2 and an appreciable increase of PDK1 (Fig. 1i
and k), suggesting an impaired mitochondrial OxPhos.
Crucial for acidosis-adapted tumor cells, which have
reprogrammed their metabolic phenotype to OxPhos,
is the up-regulation of monocarboxylate transporter 1
(MCT1), a promoter of lactate influx. Instead, tumor
cells prevalently relying on Warburg metabolism
up-regulate monocarboxylate transporter 4 (MCT4)
expression, a promoter of lactate efflux, in order to
prevent intracellular acidification and subsequent cell
death. We observed a MCT1 reduction and MCT4 in-
crease in SOX2-depleted melanoma cells (Fig. 1i and
k). Despite significant variations were obtained only
under acidic condition, we believe that MCT1 reduc-
tion with an unchanged level of MCT4 observed in
standard condition might be also indicative of a net
lactate discharge. A dynamic test of lactate production
(Fig. 1j) confirmed that SOX2 silencing in acidosis-ex-
posed melanoma cells reverted OxPhos to a more
glycolytic metabolism, further confirmed by the down-
regulation of OxPhos-related enzymes, peroxisome
proliferator-activated receptor gamma coactivator 1-α
(PGC1α), cytochrome-c (Cyt-c), cytochrome c oxidase
subunit 4 isoform 1 (COX4I), cytochrome c oxidase
subunit 5B (COX5B), ATP Synthase F1 Subunit Alpha
(ATP5A1) (Fig. 1k). Reduction of the PGC1α in both
control and acidic-exposed melanoma cells is of special
importance considering its activity in mitochondrial
biogenesis and respiration in cancer cells tightly re-
lated to malignancy [24].
Metabolic drugs sustain SOX2 contribution to OxPhos
metabolism in acidic A375-M6 melanoma cells
To further confirm the metabolic effects of SOX2
downregulation, we tested the efficacy of two meta-
bolic drugs in control and SOX2-silenced A375-M6
melanoma cells maintained in standard condition (pH
7.4) or exposed to extracellular acidosis (pH 6.7). We
used 2-Deoxy-D-glucose (2-DG, 50 mM), a glucose
analog which competitively inhibits glucose uptake and
blocks the first critical step of glucose metabolism
[25], and the mitochondrial respiration poison Metfor-
min, a well-known antidiabetic drug that targets the
complex I of the respiratory chain [26]. Treatment
with 2-DG predisposed control A375-M6 grown in
standard condition (pH 7.4) to cell death (~ 25%), but
these cytotoxic effects were almost doubled in siSOX2
melanoma cells (~ 45% cell death), suggesting their en-
hanced glycolytic dependency (Fig. 2a). On the con-
trary, Metformin treatment did not affect cell viability
neither in control nor in siSOX2 cells (~ 2.5 and 11%
cell death, respectively), demonstrating insensitiveness
to OxPhos inhibitors (Fig. 2a and b, pH 7.4). Upon
melanoma cell exposure to extracellular acidosis, 2-DG
exerted less cytotoxic effects in control cells (~ 18.5%)
compared to what observed under standard pH condi-
tion, but induced a rapid enhancement of cell death in
siSOX2 cells (~ 44.5%), disclosing a reverted attitude of
these cells to glycolytic metabolism. On the other
hand, Metformin was effective on acidic control cells
(~ 62.9% cell death), as expected, but its cytotoxic ef-
fects were significantly reduced in acidic siSOX2 cells
(~ 41.8%), highlighting a reduced OxPhos metabolism
in these cells (Fig. 2a and b, pH 6.7). These results are
consistent with our hypothesis that SOX2 down-regu-
lation promotes a glycolytic metabolism, sensitizing
melanoma cells to 2-DG and, at the same time, redu-
cing the cytotoxic effect of Metformin.
Modulation of SOX2 expression and metabolic adaptation
of SSM2c and 501-Mel melanoma cells under standard
conditions
To confirm the correlation between SOX2 and OxPhos
metabolism and evaluate the occurrence of any meta-
bolic variations, we modulated SOX2 expression in
other two human melanoma cell lines, chosen among a
panel of cell lines based on their SOX2 expression
level: patient-derived SSM2c cells, that express high
levels of SOX2, and 501-Mel cells, that express very
low SOX2 levels (Fig. 3a). When SOX2 was silenced in
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high SOX2-expressing SSM2c cells (Fig. 3b and c), be-
sides a decrease in cell proliferation (Additional file 1:
Figure S1b), we observed a significant increase of lac-
tate production (Fig. 3d) and of glycolytic genes, such
as GLUT-1, HK2, lactate dehydrogenase A (LDH-A), PDK-
1, MCT-4, coupled with a PGC1α reduction (Fig. 3e and
Additional file 1: Figure S2). Instead, when low SOX2-ex-
pressing 501-Mel were forced to express SOX2 (Fig. 3f
and g), we observed, along with increased cell proliferation
(Additional file 1: Figure S1c), a decreased release of
a
b
Fig. 2 SOX2 silencing in A375-M6 melanoma cells alters the efficacy of the metabolic drugs 2-DG and Metformin. a) Quantification chart (upper
panel) and representative pictures (lower panel) of Annexin V/PI analysis of A375-M6 treated for 24 h with the anti-glycolytic drug 2-DG (50 mM)
under standard (pH 7.4) or acidic (pH 6.7) conditions. b) Quantification chart (upper panel) and representative pictures (lower panel) of Annexin V/
PI analysis of A375-M6 treated for 24 h with the anti-OxPhos drug Metformin (10 mM) under standard (pH 7.4) or acidic (pH 6.7) conditions. *p <
0.05, **p < 0.01, ***p < 0.001, Two-way ANOVA (statistical analysis compares for each phase- early apoptosis, late apoptosis, and necrosis- siSOX2
versus the respective untreated or treated siCTRL). N = 3
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lactate in their media (Fig. 3h) and down-regulation of
glycolytic genes, such as GLUT-1, GLUT-3, HK2, LDH-A,
PDK-1, (Fig. 3i and Additional file 1: Figure S2).
Furthermore, ectopic SOX2 expression in 501-Mel in-
creased the expression of MCT-1, which generally corre-
lates with oxidative metabolism, but did not affect the
a
b
e
f
i
g h
c d
Fig. 3 Modulation of SOX2 expression induces metabolic changes in SSM2c and in 501-Mel melanoma cells. a) Western blot analysis of SOX2
expression in SK-MEL-2, SK-MEL-5, SK-MEL-28, A375-M6, 501-Mel and SSM2c melanoma cells. β-actin was used as loading control. b, c) qPCR (b) and
Western blot (c) of SOX2 in SSM2c silenced for SOX2 (LV-shSOX2) compared to control (LV-c). Quantification of SOX2 protein is shown in italic.
p < 0.05, T-test. N = 3. d) Quantification chart of lactate production of SSM2c LV-shSOX2 compared to LV-c. p < 0.05, T-test, N = 3. e) qPCR of a panel of
glycolysis- and OxPhos-related genes in SSM2c LV-shSOX2 compared to LV-c. *p < 0.05, **p < 0.01, ***p < 0.001, T-test. N = 3. f, g) qPCR (f) and Western
blot (g) of SOX2 in 501-Mel with SOX2 overexpression (pBABE-SOX2) compared to control (pBABE-c). Quantification of SOX2 protein is shown in italic.
p < 0.01, T-test. N = 3. h) Quantification chart of lactate production of 501-Mel pBABE-SOX2 compared to pBABE-c. p < 0.01, T-test, N = 3. i) qPCR of a
panel of glycolysis- and OxPhos-related genes in 501-Mel pBABE-SOX2 compared to pBABE-c. *p < 0.05, **p < 0.01, ***p < 0.001, T-test. N = 3
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other OxPhos-related genes (Fig. 3i and Additional file 1:
Figure S2). All together, these findings confirm the role of
SOX2 in OxPhos control.
SOX2-driven metabolic adaptation to OxPhos is due to
HIF1α pathway disruption
Given the results obtained after modulation of SOX2
expression in melanoma cell lines grown in acidic and
standard conditions, we hypothesized the involvement
of HIF1α transcription factor in SOX2-driven meta-
bolic adaptation. Indeed, our findings indicate that low
levels of SOX2 correlate with a blockage of the TCA
cycle mediated by either a down-regulation of PDP2 or
an up-regulation of PDK1 genes that, coupled with a
higher lactate production and the modulation of
GLUTs, HK2, LDH-A and MCTs genes, lead to the
switch toward anaerobic glycolysis. In addition, we
already know that melanoma cell exposure to extracel-
lular acidosis deeply inhibits HIF1α expression [21],
leaving tumor cells to acquire an OxPhos phenotype,
probably under the influence of the increased SOX2
expression, and able to maximize energy efficiency
with the available resources. Adaptation to extracellu-
lar acidosis elicits a reduction of the energy sensor
AMP-activated protein kinase (AMPK), which inhibits
anabolic pathways and induces cell cycle slow down,
dampening ATP consumption [7]. Acidosis-driven
HIF1α inhibition may suggest that, in certain circum-
stances, acidosis more than hypoxia could have a role
in malignant progression. To confirm our hypothesis,
we performed a bioinformatic analysis for the presence
of putative SOX2-binding sites (BS) in the HIF1A pro-
moter, and found two overlapping putative SOX2 BS in
a region encompassing − 929/− 917 bp upstream the
transcription start site (TSS) (Fig. 4a). Chromatin Im-
munoprecipitation (ChIP) showed that SOX2 binds to
the HIF1A promoter in that region (Fig. 4a), indicating
that HIF1A is a direct downstream target of SOX2. To
determine the effect of SOX2 binding on HIF1A pro-
moter, SOX2 was transfected with the HIF1A promoter
(− 2159 bp/+ 49 bp) containing the putative SOX2-BS
driven by a luciferase reporter. Luciferase assay showed
that SOX2 decreased the activity of the reporter in a
dose-dependent manner (Fig. 4b), indicating that
SOX2 inhibits HIF1α expression by directly binding to
its promoter. Thus, it was reasonable to evaluate if any
HIF1α variations occurred in response to SOX2 modu-
lation in our cellular models. SOX2 silencing in SSM2c
and A375-M6 increased the expression of HIF1α
mRNA and protein (Fig. 4c-f ). Consistently, overex-
pression of SOX2 in 501-Mel melanoma cells drastic-
ally reduced HIF1α mRNA and protein expression
(Fig. 4g and h). These results indicate that SOX2 nega-
tively regulates HIF1α in melanoma cells. It should be
considered that such variations have been observed
under normoxic conditions, when HIF1α is generally
not completely stabilized. These HIF1α variations
might be enough for the metabolic changes observed
in our experimental models of SOX2-manipulated mel-
anoma cells.
Discussion
Cancer cells are characterized by a deregulated metabol-
ism since, unlike normal cells, they largely depend on gly-
colysis even in the presence of oxygen, a phenomenon
referred to as “Warburg effect” or aerobic glycolysis [3].
Nevertheless, cancer metabolism does not exclusively de-
pend on aerobic glycolysis. Indeed, tumor cells can rather
shift between different metabolic phenotypes or be in a
hybrid state utilizing both glycolytic and oxidative metab-
olism [27]. This plasticity is also referred to cancer bio-
energetics and contributes to positively select cancer cells
in order to survive besides any environmental changes
and hostile conditions [8]. We and others have already re-
ported that the acidic microenvironment, that character-
izes most of solid tumors and is associated with aggressive
tumor phenotypes [22], favors OxPhos at the expense of
glycolysis [7, 28–32]. Here we correlate for the first time
SOX2 expression in acidic melanoma cells with a more
oxidative metabolism, that is in turn associated with
tumor progression and poor prognosis. In this regard,
OxPhos metabolism has recently regained its role in can-
cer progression, given its association with occurrence of
chemo-resistance and development of metastasis [27].
Moreover, despite the existence of controversial opin-
ions [33], recent studies suggest that cancer stem cells
are more reliant upon an oxidative metabolism than
the non-stem bulk in different tumor types, including
leukemia, ovarian, pancreatic, and breast cancer.
OxPhos metabolism has been also shown to be privi-
leged by circulating tumor cells compared to primary
tumor cells of melanoma and breast cancers [24], and
to be correlated with chemo-resistance in glioma [34],
lung [35], pancreatic [36], prostate [37], and ovarian
cancers [38]. Furthermore, several cases of metabolic
shift to OxPhos following targeted therapies have
been reported [39]. This is the case of melanomas
carrying activating BRAF mutations, where BRAF in-
hibitors induce PGC1α, a master regulator of mito-
chondrial biogenesis, which in turn promotes
oxidative metabolism [40].
By exploiting an in vitro model of extracellular acid-
osis, we demonstrated that SOX2 is induced by an
acidic microenvironment and, importantly, that SOX2
depletion in acidic melanoma cells reprograms their
metabolism to a more glycolytic phenotype, also
reducing OxPhos-related genes that characterize
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acidosis-exposed melanoma cells. The reprogramming
toward a more glycolytic profile is also evident in
SOX2-silenced cells grown in standard condition. A
tightly correlation between SOX2 and OxPhos
emerges when SOX2-silenced melanoma cells, either
grown in acidic or standard pH medium, are treated
with 2-DG and Metformin. 2-DG targets glucose me-
tabolism inducing a decrease of ATP generation,
whereas Metformin blocks complex I of the respira-
tory chain. Interestingly, epidemiological and retro-
spective studies have revealed a lower incidence of
cancer and better outcomes in diabetic patients tak-
ing Metformin compared to non-diabetics or dia-
betics using alternative drugs [41]. We found that
2-DG promotes cell death in SOX2-silenced cells
grown in standard pH conditions and, most import-
antly, also in acidic melanoma cells depleted of SOX2.
On the other hand, Metformin was effective only in
acidosis-exposed cancer cells, since its efficacy is sig-
nificantly reduced in SOX2-silenced cells, even
though a further cell death reduction could be ex-
pected. This could be probably due to the high levels
a
c d
e f
g h
b
Fig. 4 SOX2 regulates HIF1α expression in SSM2c, A375-M6 and 501-Mel melanoma cells. a) (Left) Representative image of HIF1A promoter
showing the sequence and the position of the putative SOX2-binding sites (BS) relative to the transcriptional start site (TSS). (Right) Chromatin
Immunoprecipitation (ChIP) assay showing SOX2 binding at HIF1A promoter; Actin promoter was used as negative control and set to 1. p < 0.01,
Two-way ANOVA. b) Quantification of dual-luciferase reporter assay in SSM2c cells. Relative luciferase activities were Firefly/Renilla ratios, with the
level induced by control equated to 1. Data represent mean ± s.e.m. p < 0.001 vs control, One-way ANOVA. N = 4. c, d) qPCR (c) and Western blot
(d) of HIF1α in SSM2c LV-shSOX2 compared to LV-c. Quantification of SOX2 and HIF1α protein is shown in italic. p < 0.01, T-test. N = 4. e, f) qPCR
(e) and Western blot (f) of HIF1α in A375-M6 LV-shSOX2 compared to LV-c. Quantification of SOX2 and HIF1α protein is shown in italic. p < 0.05,
T-test. N = 4. g, h) qPCR (g) and Western blot (h) of HIF1α in 501-Mel pBABE-SOX2 compared to pBABE-c. Quantification of SOX2 and HIF1α
protein is shown in italic. p < 0.01, T-test. N = 4. HSP90 was used as loading control
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of SOX2 in acidic melanoma cells associated with an
only partial SOX2 silencing efficacy.
To better understand SOX2 contribution in OxPhos
metabolism, we determined metabolic markers in SSM2c
cells, characterized by high SOX2 levels, and in 501-Mel,
which show low/no SOX2 expression, upon knock-down
or ectopic expression of SOX2, respectively. We con-
firmed the ability of SOX2 to contribute to an oxidative
metabolism. Indeed, SOX2 knock-down leads to the sup-
pression of the master regulator of mitochondrial me-
tabolism PGC1α, a phenomenon associated with the
promotion of critical steps of the glycolytic pathway, i.e.
GLUTs, HK2, PDP2/PDK1 axis and LDH-A. Further-
more, SOX2 silencing induces a switch of MCT genes
from type 1 to type 4, indicating a preferred lactate
efflux characteristic of a glycolytic metabolism. Consist-
ently, in SOX2 overexpressing 501-Mel cells the reduc-
tion of most glycolytic markers came together with a
promotion of MCT-1, a promoter of lactate influx. The
clinical importance of MCT expression levels derived
from their tightly correlation with shorter overall sur-
vival of advanced melanoma patients [42].
SOX2 has been already associated with tumor initi-
ation, growth, drug resistance, and metastasis. Chemo-
resistant cancer cells that appear to preferably exploit
oxidative metabolism, have been also associated with en-
hanced SOX2 expression in gastric, lung, prostate, colo-
rectal [11], and breast [43] cancers. These findings
prompted us to verify whether SOX2 influence in cell
metabolism might be related to HIF1α activity, consider-
ing that HIF1α strongly induces a glycolytic phenotype.
Our results indicate that HIF1α and SOX2 are inversely
correlated in normoxic condition, and this effect might
be functionally sufficient to reprogram melanoma cells
toward OxPhos. This is likely true mainly in conditions
when SOX2 exceeds HIF1α in terms of protein expres-
sion, as in the case of acidosis-exposed melanoma cells.
Instead, under hypoxia, HIF1α stabilization, despite the
presence of SOX2 [44], likely represents the leading fac-
tor that causes cancer cell metabolic switch to anaerobic
glycolysis. Among the so-called non-canonical HIF1α
regulation [45], it is quite interesting to recall that an in-
creased lactate production is able to promote HIF1α
stabilization, although the mechanism has not been yet
clarified [46]. Thus, the lactate increase observed in
SOX2-silenced acidic and non-acidic melanoma cells
could be able to contribute to HIF1α expression and
glycolytic re-conversion. Furthermore, quite recently it
was demonstrated that HIF1α represses PGC1α expres-
sion in renal cell carcinoma, suggesting a regulatory loop
among these transcriptional factors, involving oxygen
sensing to mitochondrial biogenesis [47]. This is in line
with our findings, i.e. PGC1α reduction and HIF1α pro-
motion upon SOX2 silencing.
Conclusions
In conclusion, with this study we would propose a thigh
correlation between SOX2 expression and OxPhos me-
tabolism in melanoma cells, under a condition of re-
duced HIF1α expression. Oxidative metabolism might be
of a crucial importance for melanoma progression. In-
deed, cancer cells may take advantage of this metabolic
reprogramming toward OxPhos contributing to the de-
velopment of an aggressive tumor phenotype endowed
with an enhanced drug resistance and metastatic ability
[48].
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